DFFN Stock Discussion

CervoMed Inc. Description

CervoMed Inc. is a clinical-stage biotechnology company advancing CNS-focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in dementia with Lewy bodies (DLB) and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Development Cancer Treatment Oncology Chemotherapy Radiation Ophthalmology Oxygen Dermatology Macular Degeneration Blastoma Radiation Therapy Glioblastoma Signal Transduction Cancer Cell Acne Brain Tumor mTOR Glioblastoma Multiforme Oncology Applications Acne Vulgaris